Log in

OTCMKTS:GBIMGlobeImmune Stock Price, Forecast & News

$0.30
-0.13 (-30.09 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.30
Now: $0.30
$0.33
50-Day Range
$0.08
MA: $0.31
$0.48
52-Week Range
$0.06
Now: $0.30
$0.49
Volume7,850 shs
Average Volume11,655 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta1.91
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GBIM
Previous SymbolNASDAQ:GBIM
CUSIPN/A
Phone303-625-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees2
Next Earnings DateN/A
OptionableNot Optionable
$0.30
-0.13 (-30.09 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GBIM News and Ratings via Email

Sign-up to receive the latest news and ratings for GBIM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GlobeImmune (OTCMKTS:GBIM) Frequently Asked Questions

How has GlobeImmune's stock been impacted by COVID-19 (Coronavirus)?

GlobeImmune's stock was trading at $0.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GBIM stock has increased by 200.6% and is now trading at $0.3006.
View which stocks have been most impacted by Coronavirus
.

How were GlobeImmune's earnings last quarter?

GlobeImmune Inc (OTCMKTS:GBIM) announced its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.12. The biopharmaceutical company earned $0.94 million during the quarter.
View GlobeImmune's earnings history
.

Has GlobeImmune been receiving favorable news coverage?

Headlines about GBIM stock have been trending very negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GlobeImmune earned a coverage optimism score of -3.4 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about GlobeImmune
.

Who are some of GlobeImmune's key competitors?

What other stocks do shareholders of GlobeImmune own?

Who are GlobeImmune's key executives?

GlobeImmune's management team includes the following people:
  • Mr. C. Jeffrey Dekker CPA, Pres, VP of Fin., Treasurer, Sec. and Director (Age 54)
  • Dr. Richard C. Duke, Scientific Founder & Member of Scientific Advisory Board
  • Dr. Donald Bellgrau, Scientific Founder & Chairman of The Scientific Advisory Board
  • Mr. Thomas A. Keuer, Acting Head of Manufacturing Operations (Age 60)
  • Dr. Allen L. Cohn M.D., Exec. Director Clinical Devel. (Age 61)

What is GlobeImmune's stock symbol?

GlobeImmune trades on the OTCMKTS under the ticker symbol "GBIM."

How do I buy shares of GlobeImmune?

Shares of GBIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GlobeImmune's stock price today?

One share of GBIM stock can currently be purchased for approximately $0.30.

What is GlobeImmune's official website?

The official website for GlobeImmune is www.globeimmune.com.

How can I contact GlobeImmune?

GlobeImmune's mailing address is 1450 INFINITE DRIVE, LOUISVILLE CO, 80027. The biopharmaceutical company can be reached via phone at 303-625-2700 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.